海通国际发表研究报告指,映恩生物(09606.HK) 去年实现收入18.5亿元人民币,按年跌5%,主要来自于许可及合作协议收入。研发费用8.4亿元人民币,按年基本持平。全年归母净亏损26亿元人民币,2024年同期为亏损10.5亿元人民币,主要受公司在香港市场上市,优先股转股的金融负债公允价值变动一次性影响。该行结合映恩生物临床管线推进情况,调整公司可能收到来自BioNTech的远期销售分成预测,并...
Source Link海通国际发表研究报告指,映恩生物(09606.HK) 去年实现收入18.5亿元人民币,按年跌5%,主要来自于许可及合作协议收入。研发费用8.4亿元人民币,按年基本持平。全年归母净亏损26亿元人民币,2024年同期为亏损10.5亿元人民币,主要受公司在香港市场上市,优先股转股的金融负债公允价值变动一次性影响。该行结合映恩生物临床管线推进情况,调整公司可能收到来自BioNTech的远期销售分成预测,并...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.